Franka Menge

Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’

Patrick Schöffski, Olivier Mir, Bernd Kasper et al. · European Journal of Cancer · 2020 · 67 citations

Medicine, Oncology, Pharmacology +12

Prognosis of Patients with Metastatic Soft Tissue Sarcoma: Advances in Recent Years

Jakob Lochner, Franka Menge, Nikolaos Vassos et al. · Oncology Research and Treatment · 2020 · 67 citations

Medicine, Oncology, Pathology +8

Primary and secondary angiosarcomas: a comparative single-center analysis

Thorsten Hillenbrand, Franka Menge, Peter Hohenberger et al. · Clinical Sarcoma Research · 2015 · 29 citations · Full text

Medicine, Oncology, Surgery +14

Trauma and sporadic desmoid tumor development: An approach toward real incidence and aspects of causality

Peter Hohenberger, Franka Menge, Ralph Hohenberger et al. · Cancer · 2023 · 16 citations · Full text

Medicine, Oncology, Surgery +16

Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.

Patrick Schöffski, Olivier Mir, Bernd Kasper et al. · Journal of Clinical Oncology · 2019 · 12 citations

Medicine, Oncology, Pharmacology +17